Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy B Niewold

Showing results (61-70 of 181) with videos related to

Pageof 19
Sort By:
Gene|February 13, 2016
Genetic data: The new challenge of personalized medicine, insights for rheumatoid arthritis patientsGeorge N Goulielmos, Maria I Zervou, Effie Myrthianou, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|January 25, 2020
Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid ArthritisElizaveta Efuni, Samuel Cytryn, Patrick Boland, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|July 11, 2009
Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experienceLinda M Mileti, Mary E Strek, Timothy B Niewold, et al.
Arthritis Research & Therapy|May 1, 2019
High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosusVilija Oke, Iva Gunnarsson, Jessica Dorschner, et al.
EMBO Molecular Medicine|January 27, 2011
A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patientsJulien Pothlichet, Timothy B Niewold, Damien Vitour, et al.
Arthritis and Rheumatism|May 28, 2010
Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cellsSheela Shrestha, Barry Wershil, John F Sarwark, et al.
Current Opinion in Immunology|November 27, 2020
Type I interferon in the pathogenesis of systemic lupus erythematosusMariana Postal, Jessica F Vivaldo, Ruth Fernandez-Ruiz, et al.
Archives of Neurology|July 18, 2012
Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statinsXuan Feng, Diana Han, Bharat K Kilaru, et al.
Lupus Science & Medicine|September 14, 2022
Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritisAliisa Häyry, Francesca Faustini, Agneta Zickert, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|February 5, 2010
Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myelomaRichard J Lin, James J Curran, Todd M Zimmerman, et al.
Pageof 19

Showing results (61-70 of 181) with videos related to

Sort By:
Pageof 19
Gene|February 13, 2016
Genetic data: The new challenge of personalized medicine, insights for rheumatoid arthritis patientsGeorge N Goulielmos, Maria I Zervou, Effie Myrthianou, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|January 25, 2020
Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid ArthritisElizaveta Efuni, Samuel Cytryn, Patrick Boland, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|July 11, 2009
Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experienceLinda M Mileti, Mary E Strek, Timothy B Niewold, et al.
Arthritis Research & Therapy|May 1, 2019
High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosusVilija Oke, Iva Gunnarsson, Jessica Dorschner, et al.
EMBO Molecular Medicine|January 27, 2011
A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patientsJulien Pothlichet, Timothy B Niewold, Damien Vitour, et al.
Arthritis and Rheumatism|May 28, 2010
Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cellsSheela Shrestha, Barry Wershil, John F Sarwark, et al.
Current Opinion in Immunology|November 27, 2020
Type I interferon in the pathogenesis of systemic lupus erythematosusMariana Postal, Jessica F Vivaldo, Ruth Fernandez-Ruiz, et al.
Archives of Neurology|July 18, 2012
Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statinsXuan Feng, Diana Han, Bharat K Kilaru, et al.
Lupus Science & Medicine|September 14, 2022
Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritisAliisa Häyry, Francesca Faustini, Agneta Zickert, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|February 5, 2010
Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myelomaRichard J Lin, James J Curran, Todd M Zimmerman, et al.
Pageof 19